Patients with advanced lung cancer: Is there scope to discontinue inappropriate medication?

International Journal of Clinical Pharmacy

Volumn 35, Issue 2, 2013, Pages 181-184

  Todd, Adam ^a,b   Williamson, Steve ^c   Husband, Andy ^a,b   Baqir, Wasim ^c   Mahony, Mairead ^a  

^a UNIVERSITY OF SUNDERLAND   (United Kingdom)

^b DURHAM UNIVERSITY   (United Kingdom)

^c NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Erlotinib; Inappropriate medication; Limited life expectancy; Lung cancer; Medication review; Polypharmacy

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; ERLOTINIB; PROTON PUMP INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG ABSORPTION; GENERAL PRACTITIONER; HUMAN; INAPPROPRIATE PRESCRIBING; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MEDICAL ASSESSMENT; MEDICAL ONCOLOGIST; MULTICENTER STUDY (TOPIC); NURSE PRACTITIONER; PATIENT HISTORY OF THERAPY; PHARMACIST; POLYPHARMACY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT OUTCOME; UNITED KINGDOM; DRUG INTERACTION; LUNG TUMOR; MULTICENTER STUDY; PATHOLOGY; PREVALENCE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG INTERACTIONS; ENGLAND; HUMANS; INAPPROPRIATE PRESCRIBING; LUNG NEOPLASMS; POLYPHARMACY; PREVALENCE; PROTEIN KINASE INHIBITORS; PROTON PUMP INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES;

EID: 84884490770     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9731-2     Document Type: Article

References (16)

1. Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38: 666-71.
2. Hanlon JT, Schmader KE, Koronkowski MJ, Weinberger M, Landsman PB, Samsa GP, et al. Adverse drug events in high-risk older outpatients. J Am Geriatr Soc. 1997;45: 945-8.
3. Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12: 1249-57.
4. Riechelmann RP, Zimmermann C, Chin SN, Wang L, O'Carroll A, Zarinehbaf S, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manag. 2008;35: 535-43.
5. Girre V, Arkoub H, Puts MT, et al. Potential drug interactions in elderly cancer patients. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol. 2011;78: 220-6.
6. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35: 692-706.
7. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166: 605-9.
8. Fede A, Miranda M, Antonangelo D, Trevizan L, Schaffhausser H, Hamermesz B, et al. Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer. 2011;19: 1313-8.
9. Stavrou EP, Buckley N, Olivier J, Pearson SA. Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open. 2012;2:e000880.
10. Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract. 2012;13: 56.
11. Tarceva Summary of Product Characteristics. Available at http://www.medicines.org.uk/EMC/medicine/16781/SPC/Tarceva? 25mg%2c?100mg?and? 150mg?Film-Coated?Tablets/. Accessed 21 Nov 2012.
12. Conlon LS, Romero-Ortuno R, Smyth B, Ryan R, Cogan L. General and risk management, patient safety (including: medication errors, quality control): the effect of pharmacist intervention on psychotropic prescribing through clinical medication review in a long-term care hospital in Dublin. Eur J Hosp Pharm. 2012;19: 127-8.
13. Gallagher P, Ryan C, Byrne S. STOPP (screening tool of older person's prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46: 72-83.
14. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163: 2716-24.
15. Maddison AR, Fisher J, Johnston G. Preventive medication use among persons with limited life expectancy. Prog Palliat Care. 2011;19: 15-21.
16. Hilton JF, Seymour J, Le Maitre A, Tu D, Shepherd FA and Bradbury PA. An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib. J Clin Oncol. 2011;29(suppl) (abstr 7523).